-
Views
-
Cite
Cite
Poster Session 2: Sunday, 21 October 2012 - 14:00 - 18:00, European Heart Journal. Acute Cardiovascular Care, Volume 1, Issue 1_suppl, 1 October 2012, Pages 60–97, https://doi.org/10.1177/2048872612461726e
- Share Icon Share
Extract
Acute coronary syndromes: STEMI
192 Roles of matrix metalloproteinases in the assessment of the in-hospital prognosis in patients with ST-segment elevation myocardial infarction
T Pecherina, V Kashtalap, O Barbarash
Research Institute for Complex Issues of Cardiov. Dis. - Siberian Branch RAMS Institution Scientific, Kemerovo, Russian Federation
Nowadays, the role of matrix metalloproteinases (MMPs) as independent predictors of future cardiovascular events in patients with myocardial infarction (MI) is actively debated. However, the previous studies results are contradictory and presuppose further investigation of their prognostic significance in patients with MI.
Aims
To study the matrix metalloproteinases role in recurrent cardiovascular events in-hospital prognosis in ST-segment elevation myocardial infarction patients (STEMI).
Material and methods
175 patients with diagnosed STEMI were consecutively enrolled in this prospective study. The average patients age in the total group was 61.3 (33, 89) years including 116 male patients (66.3%) and 59 - female (33.7%). Blood serum levels of MMP-1, 3, 9 (ng / ml) were detected by ELISA in all patients at the admission time (day 1) and dynamically at day 12 from the disease onset. All STEMI patients were divided into two groups according the in-hospital outcome: positive and adverse outcomes. The adverse included: death, recurrent myocardial infarction, acute cerebral blood flow or transient ischemic attack, life-threatening arrhythmias, early post-infarction angina. The reference values of MMP-1 were 0, 912-9, 34, MMP-3: 4, 8-82, 4; and MMP -9: 98-705 ng / ml.
Comments